Revised SPC: Tecentriq (atezolizumab) 840 mg concentrate for solution for infusion

Severe cutaneous adverse reactions occurred in 0.7% (24/3,568) of patients who received atezolizumab monotherapy. The median time to onset was 5.9 months (range: 0.1 to 15.5 months) and the median duration was 1.6 months (range: 0 to 22.1+ months).

Source:

electronic Medicines compendium